Log in

LON:AGYAllergy Therapeutics Share Price, Forecast & News

GBX 14
0.00 (0.00 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
13.77
Now: GBX 14
14.50
50-Day Range
10.75
MA: GBX 12.08
14.45
52-Week Range
0.12
Now: GBX 14
14.50
Volume160,968 shs
Average Volume167,682 shs
Market Capitalization£89.06 million
P/E Ratio11.67
Dividend YieldN/A
BetaN/A
Allergy Therapeutics plc engages in the research and development of allergy treatments. It sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies, particularly to grasses, weeds, and trees. The company's products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, and Venomil. It also develops clinical pipeline products that include vaccines for grass, tree, and house dust mite, as well as a peanut allergy vaccine that is in pre-clinical stage. The company primarily sells its products in European countries. Allergy Therapeutics plc was founded in 1934 and is based in Worthing, the United Kingdom.
Read More
Allergy Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.02 out of 5 stars


Industry, Sector and Symbol

Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-1903-844700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£77.48 million
Cash FlowGBX 6.55 per share
Book ValueGBX 8 per share

Profitability

Miscellaneous

Employees500
Market Cap£89.06 million
Next Earnings DateN/A
OptionableNot Optionable

Receive AGY News and Ratings via Email

Sign-up to receive the latest news and ratings for AGY and its competitors with MarketBeat's FREE daily newsletter.

Allergy Therapeutics (LON:AGY) Frequently Asked Questions

How has Allergy Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Allergy Therapeutics' stock was trading at GBX 9.25 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AGY shares have increased by 51.4% and is now trading at GBX 14. View which stocks have been most impacted by Coronavirus.

How were Allergy Therapeutics' earnings last quarter?

Allergy Therapeutics plc (LON:AGY) posted its earnings results on Wednesday, March, 4th. The company reported $2.40 EPS for the quarter. View Allergy Therapeutics' earnings history.

Has Allergy Therapeutics been receiving favorable news coverage?

News headlines about AGY stock have been trending somewhat negative this week, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Allergy Therapeutics earned a daily sentiment score of -1.2 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news about Allergy Therapeutics.

Who are some of Allergy Therapeutics' key competitors?

What other stocks do shareholders of Allergy Therapeutics own?

Who are Allergy Therapeutics' key executives?

Allergy Therapeutics' management team includes the following people:
  • Mr. Manuel Llobet, CEO & Exec. Director (Age 55)
  • Mr. Nicolas Alexander Ulrich Wykeman, CFO & Director (Age 54)
  • Ms. Beverly Lees, Group Operations Director
  • Dr. Murray Skinner, Chief Scientific Officer
  • Mr. Santiago Puig, Bus. Devel. Director

What is Allergy Therapeutics' stock symbol?

Allergy Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "AGY."

How do I buy shares of Allergy Therapeutics?

Shares of AGY and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Allergy Therapeutics' stock price today?

One share of AGY stock can currently be purchased for approximately GBX 14.

How big of a company is Allergy Therapeutics?

Allergy Therapeutics has a market capitalization of £89.06 million and generates £77.48 million in revenue each year. Allergy Therapeutics employs 500 workers across the globe.

What is Allergy Therapeutics' official website?

The official website for Allergy Therapeutics is www.allergytherapeutics.com.

How can I contact Allergy Therapeutics?

Allergy Therapeutics' mailing address is Dominion Way, WORTHING, BN14 8SA, United Kingdom. The company can be reached via phone at +44-1903-844700.

This page was last updated on 7/11/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.